Table 1.
Comparison of tumor characteristics between age groups
| Variable | Value | Total patients (N=123) | Patients <40 years (N=47) | Patients >40 years (N=76) | p-value | Missing data |
|---|---|---|---|---|---|---|
| T | 1 | 43.9% (54) | 38.3% (18) | 47.4% (36) | 0.019* | 0 |
| 2 | 43.9% (54) | 40.4% (19) | 46.1% (35) | |||
| 3 | 8.9% (11) | 19.1% (9) | 2.6% (2) | |||
| 4 | 3.3% (4) | 2.1% (1) | 3.9% (3) | |||
| N | 0 | 53.3% (65) | 45.7% (21) | 57.9% (44) | 0.631 | 1 |
| 1 | 32.8% (40) | 39.1% (18) | 28.9% (22) | |||
| 2 | 9.8% (12) | 10.9% (5) | 9.2% (7) | |||
| 3 | 4.1% (5) | 4.3% (2) | 3.9% (3) | |||
| Stage | I | 32.5% (40) | 23.4 (11) | 38.2% (29) | 0.141 | 0 |
| II | 45.5% (56) | 46.8% (22) | 44.7% (34) | |||
| III | 22% (27) | 29.8% (14) | 17.1% (13) | |||
| Grade | 1 | 17.2% (21) | 15.2% (7) | 18.4% (35) | 0.801 | 1 |
| 2 | 45.1% (55) | 43.5% (20) | 46.1% (35) | |||
| 3 | 37.7% (46) | 41.3% (19) | 35.5% (27) | |||
| Type | IDC | 87.6% (106) | 82.6% (38) | 90.7% (68) | 0.182 | 2 |
| ILC | 9.1% (11) | 15.2% (7) | 5.3% (4) | |||
| IDC and ILC | 2.2% (1) | 4% (3) | ||||
| Tumor size (mean), cm | 2.6 | 2.7 | 0.8 | |||
| LVI | No | 62.1% (72) | 53.5% (23) | 67.1% (49) | 0.168 | 7 |
| Yes | 37.9% (44) | 46.5% (20) | 32.9% (24) | |||
| ER | Negative | 18% (22) | 21.3% (10) | 16% (12) | 0.210 | 1 |
| Weakly positive | 7.4% (9) | 12.8% (6) | 4% (3) | |||
| Moderately positive | 35.2% (43) | 34% (16) | 36% (27) | |||
| Strongly positive | 39.3% (48) | 31.9% (15) | 44% (33) | |||
| PR | Negative | 27% (33) | 31.9% (15) | 24% (18) | 0.310 | 1 |
| Weakly positive | 13.9% (17) | 19.1% (9) | 10.7% (8) | |||
| Moderately positive | 29.5% (36) | 23.4% (11) | 33.3% (25) | |||
| Strongly positive | 29.5% (36) | 25.5% (12) | 32% (24) | |||
| HER2 | Negative | 74.6% (91) | 26% (33) | 47% (58) | 0.4 | 1 |
| Positive | 25.4% (31) | 11.4% (14) | 14% (17) | |||
| Subtype | Luminal A | 41% (50) | 38.3% (18) | 42.7% (32) | 0.565 | 1 |
| Luminal B | 32% (39) | 27.7% (13) | 34.7% (26) | |||
| Triple negative | 19.7% (24) | 25.5% (12) | 16% (12) | |||
| Erb-B2 | 7.4% (9) | 8.5% (4) | 6.7% (5) |
Note:
*
Fisher’s exact test was used for cells containing <5% data.
Abbreviations: IDC, intraductal carcinoma; ILC, intralobular carcinoma; LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor.